Theragenics Galt VTI Valved Tearaway Introducer
The Galt VTI is a tearaway introducer that includes an ergonomic low-profile patent-pending integrated valve. The Galt VTI allows surgeons the ability to introduce or provide access for other medical devices to enter into a patient’s vascular system, reducing the risk of an air embolism and leakage. It is also less bulky and more compact than similar products currently available.
The addressable market in the United States for the Galt VTI is estimated to be approximately $14 million of annual sales and growing at 5 percent annually. The Galt VTI is expected to launch in the second half of 2012, with revenue in the range of $300,000 expected based on indications of interest from Galt Medical’s customer base. Within twelve months of launch, the company expects the Galt VTI to generate annualized revenue of $1 million to $2 million, with gross profit margins higher than currently being realized in Galt Medical’s surgical products segment.
Galt Medical is a wholly-owned subsidiary of Theragenics. The Galt business unit manufactures and distributes vascular access products, including introducers and guidewires used in interventional radiology, interventional cardiology and vascular surgery. Theragenics operates two business segments: its surgical products business and its brachytherapy seed business.
Theragenics Corp. received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Galt VTI valved tearaway introducer in April 2012.
For more information: www.theragenics.com